Related Experiment Video

Updated: Jun 11, 2026

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

Therapeutic approaches to epileptogenesis--hope on the horizon

Asla Pitkänen1

  • 1Epilepsy Research Laboratory, AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. asla.pitkanen@uef.fi

Epilepsia
|July 13, 2010
PubMed

Insights

Novel treatments show promise in preventing epileptogenesis, a critical medical need. Research highlights immunosuppressants and plasticity modifiers, alongside unexpected drug effects in epilepsy models, offering new therapeutic avenues.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Epileptogenesis prevention remains a significant unmet medical need.
  • Recent preclinical studies show promising results for novel treatments targeting genetic and acquired epilepsy.
  • Existing research explores immunosuppressants, cellular adhesion modifiers, and plasticity-altering therapies.

Purpose of the Study:

  • To review recent preclinical findings on preventing epileptogenesis.
  • To introduce a novel scheme for defining epileptogenesis-related terms.
  • To discuss critical caveats in interpreting preclinical epilepsy research data.

Main Methods:

  • Literature review of preclinical studies on epileptogenesis prevention.
  • Analysis of treatments including immunosuppressants, cellular adhesion modifiers, and plasticity modulators.
  • Examination of antiepileptic drugs and proconvulsants in epilepsy models.

Main Results:

  • Several novel treatments demonstrate favorable effects on genetic and acquired epileptogenesis in preclinical models.
  • Unexpected positive outcomes were observed with antiepileptic drugs in genetic epilepsy and proconvulsants in acquired epilepsy.
  • Key factors influencing study interpretation include genetic background, insult severity, seizure monitoring, and population size.

Conclusions:

  • Preclinical research offers encouraging insights into preventing epileptogenesis.
  • Careful consideration of experimental design and interpretation is crucial for advancing the field.
  • A standardized terminology for epileptogenesis is proposed to improve research clarity.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...